Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -348.00% | -752.06% | -71,233.33% | 99.87% | 61.79% |
| Total Depreciation and Amortization | 0.00% | -28.57% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 570.10% | 186.90% | -- | -- | -- |
| Change in Net Operating Assets | 227.12% | 101.59% | -2,497,833.33% | -99.66% | -77.46% |
| Cash from Operations | 35.60% | 93.31% | -- | 100.00% | 31.73% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -- | -- | 31.25% |
| Cash from Investing | 100.00% | 98.31% | -- | -- | 31.25% |
| Total Debt Issued | -- | -100.00% | -- | -- | -28.79% |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -- | -31.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.97% | -147.87% | -- | -- | -27.91% |